Related Experiment Videos
Does AIDS impair the absorption of antituberculosis agents?
1Department of Pharmacology, University of Cape Town Medical School, Observatory, Western Cape, South Africa.
Summary
Human immunodeficiency virus (HIV) infection does not appear to lower tuberculosis drug levels. This study found no significant differences in drug bioavailability between HIV-infected and HIV-negative tuberculosis patients.
Area of Science:
- Pharmacokinetics
- Infectious Diseases
- HIV/AIDS Research
Background:
- Therapeutic drug monitoring (TDM) suggested for HIV-positive tuberculosis patients due to reported low drug concentrations.
- Concerns about treatment failure and drug resistance in co-infected individuals.
Purpose of the Study:
- To determine if human immunodeficiency virus (HIV) infection alters the bioavailability of antituberculosis drugs.
- Investigate potential pharmacokinetic differences in co-infected patients.
Main Methods:
- A pharmacokinetic trial involving 27 hospitalized tuberculosis patients (13 with AIDS, 14 HIV-negative).
- Standardized doses of isoniazid, rifampicin, and pyrazinamide administered under supervision.
- Plasma drug concentrations measured over 12 hours to determine Cmax, Tmax, and AUC.
Main Results:
- No significant differences in Cmax, Tmax, and AUC for isoniazid and pyrazinamide between HIV-positive and HIV-negative groups.
- HIV-positive patients (AIDS) showed a significantly greater area-under-the-concentration-time curve (AUC) for rifampicin compared to controls.
- No significant differences in Cmax and Tmax for rifampicin were observed.
Conclusions:
- The study found no evidence that HIV infection reduces the plasma concentrations of commonly used antituberculosis drugs.
- Results suggest that standard dosing may be appropriate for HIV-infected tuberculosis patients.
- Further research may be needed to fully understand rifampicin pharmacokinetics in this population.